Eliminate Viral Hepatitis

Each year, around 630 Australians and 500,000 people globally die from hepatitis C-related causes.

Eliminating hepatitis C virus (HCV) in Australia is now a possibility, with the listing of direct-acting antiviral (DAA) drugs on the PBS. But this is one step in the path towards elimination.

Burnet will also make a major contribution in global efforts to eliminate hepatitis B & C as major health threats. This includes supporting vital research underway by our researchers to create a novel, effective, low-cost HCV vaccine suitable for resource-constrained countries.

Burnet Institute’s Eliminate Viral Hepatitis strategy is focussed on:

  • Achieving a 50 percent reduction in hepatitis C prevalence in Australia by 2020.
  • Supporting the achievement of the WHO’s hepatitis C elimination targets in Australia before 2030 with key partners.
  • Working towards Global WHO viral hepatitis elimination strategy by addressing diagnosis, delivery of direct-acting antivirals, prevention and vaccine development.

Working together, with research organisations, governments, the community and affected populations, Burnet will help change the course of hepatitis C infection and its impact as a public health threat.

Hepatitis C virus (HCV) affects more than 250,000 Australians resulting in up to 630 deaths from liver cancer and liver failure each year. Globally, more than 500,000 people die from HCV-related causes.

The ambitious journey to eliminate viral hepatitis has begun.


Contact Details

Professor Margaret Hellard AM

Deputy Director (Programs); Adjunct Professor, Monash University, DEPM.






Latest News

    11 October, 2019

    Tall Poppy award for Dr Joseph Doyle

    Burnet’s Dr Joe Doyle has been acknowledged for his work in the prevention of blood-borne viruses with a prestigious Tall Poppy Award.

    24 September, 2019

    The case for a hepatitis C vaccine

    New Burnet research highlights the urgent need to develop a universal hepatitis C vaccine to meet the WHO goal for elimination.

Upcoming Events

    02 December, 2019


    AVS10, the Australasian Virology Society’s 10th biennial meeting, will be held in Queenstown, New Zealand, from 2-5 December.